85. Treatment Outcomes of Group B Streptococcus Infection in Neonates: Scoping Review
Main Article Content
Abstract
Evaluation of Treatment Outcomes for Group B Streptococcus Infection in Neonates. This systematic review aims to evaluate the effectiveness of treatment strategies for Group B Streptococcus (GBS) infection in neonates. Relevant studies reporting treatment outcomes for neonatal GBS infection were identified through a comprehensive search of electronic databases, including PubMed. A total of 16 studies met the inclusion criteria, encompassing 6770 neonatal patients. The analysis focused on treatment efficacy, mortality rates, complications and long-term sequelae, patterns of antibiotic resistance, and therapeutic approaches used in the management of neonatal GBS infection. Reported mortality ranged from 4.7% to 14.3%, neurological sequelae from 8.3% to 40%, and respiratory failure was the most frequent complication (3 – 64%). Penicillin and ampicillin remained the first-line antibiotics with 100% susceptibility, whereas resistance to erythromycin and clindamycin was high (20.8 – 92.5%). Neonatal GBS infection remains a serious threat, particularly in preterm infants. Early recognition with appropriate antibiotics and intensive support is key to improving prognosis.
Article Details
Keywords
Group B Streptococcus, neonatal infection, treatment, neurological sequelae, antibiotic resistance
References
2. Jennings HJ, Katzenellenbogen E, Lugowski C, Kasper DL. Structure of native polysaccharide antigens of type Ia and type Ib group B Streptococcus. Biochemistry. 1983;22(5):1258-1264. doi:10.1021/bi00274a042
3. Wessels MR, Benedí WJ, Jennings HJ, Michon F, DiFabio JL, Kasper DL. Isolation and characterization of type IV group B Streptococcus capsular polysaccharide. Infect Immun. 1989;57(4):1089-1094. doi:10.1128/iai.57.4.1089-1094.1989
4. Schrag S, Gorwitz R, Fultz-Butts K. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2002;51(RR-11):1-22.
5. Prevention of Perinatal Group B Streptococcal Disease: A Public Health Perspective. Accessed April 22, 2024. https://www.cdc.gov/mmwr/preview/mmwrhtml/00043277.htm
6. Joubrel C, Tazi A, Six A, et al. Group B streptococcus neonatal invasive infections, France 2007-2012. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2015;21(10):910-916. doi:10.1016/j.cmi.2015.05.039
7. Dong Y, Jiang SY, Zhou Q, Cao Y. Group B Streptococcus causes severe sepsis in term neonates: 8 years experience of a major Chinese neonatal unit. World J Pediatr WJP. 2017;13(4):314-320. doi:10.1007/s12519-017-0034-5
8. Molecular characteristics of group B Streptococcus isolates from infants in southern mainland China | BMC Infectious Diseases | Full Text. Accessed July 10, 2025. https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-019-4434-0
9. Lo CW, Liu HC, Lee CC, et al. Serotype distribution and clinical correlation of Streptococcus agalactiae causing invasive disease in infants and children in Taiwan. J Microbiol Immunol Infect Wei Mian Yu Gan Ran Za Zhi. 2019;52(4):578-584. doi:10.1016/j.jmii.2017.09.002
10. Kao Y, Tsai MH, Lai MY, et al. Emerging serotype III sequence type 17 group B streptococcus invasive infection in infants: the clinical characteristics and impacts on outcomes. BMC Infect Dis. 2019;19(1):538. doi:10.1186/s12879-019-4177-y
11. Kang HM, Lee HJ, Lee H, et al. Genotype Characterization of Group B Streptococcus Isolated From Infants With Invasive Diseases in South Korea. Pediatr Infect Dis J. 2017;36(10):e242-e247. doi:10.1097/INF.0000000000001531
12. Wang P, Ma Z, Tong J, et al. Serotype distribution, antimicrobial resistance, and molecular characterization of invasive group B Streptococcus isolates recovered from Chinese neonates. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2015;37:115-118. doi:10.1016/j.ijid.2015.06.019
13. Andersen M, Smith B, Murra M, Nielsen SY, Slotved HC, Henriksen TB. Invasive group B Streptococcus strains and clinical characteristics in Danish infants from 1999 to 2009. Front Microbiol. 2022;13:1001953. doi:10.3389/fmicb.2022.1001953
14. Ding Y, Wang Y, Hsia Y, Russell N, Heath PT. Systematic Review and Meta-Analyses of Incidence for Group B Streptococcus Disease in Infants and Antimicrobial Resistance, China. Emerg Infect Dis. 2020;26(11):2651-2659. doi:10.3201/eid2611.181414
15. Andersen M, Murra M, Nielsen SY. Invasive group B Streptococcus strains and clinical characteristics in Danish infants from 1999 to 2009. Front Microbiol. 2022;13:1001953. doi:10.3389/fmicb.2022.1001953
16. Etiological serotype and genotype distributions and clinical characteristics of group B streptococcus-inducing invasive disease among infants in South China | BMC Pediatrics | Full Text. Accessed July 10, 2025. https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-020-02048-2
17. Mynarek M, Bjellmo S, Lydersen S, Afset JE, Andersen GL, Vik T. Incidence of invasive Group B Streptococcal infection and the risk of infant death and cerebral palsy: a Norwegian Cohort Study. Pediatr Res. 2021;89(6):1541-1548. doi:10.1038/s41390-020-1092-2
18. Creti R, Imperi M, Berardi A, et al. Invasive Group B Streptococcal Disease in Neonates and Infants, Italy, Years 2015-2019. Microorganisms. 2021;9(12):2579. doi:10.3390/microorganisms9122579
19. Clinical and Laboratory Features of Group B Streptococcus Meningitis in Infants and Newborns: Study of 848 Cases in France, 2001–2014 | Clinical Infectious Diseases | Oxford Academic. Accessed July 10, 2025. https://academic.oup.com/cid/article/66/6/857/4554470
20. Nanduri SA, Petit S, Smelser C, et al. Epidemiology of Invasive Early-Onset and Late-Onset Group B Streptococcal Disease in the United States, 2006 to 2015: Multistate Laboratory and Population-Based Surveillance. JAMA Pediatr. 2019;173(3):224-233. doi:10.1001/jamapediatrics.2018.4826